Our Approach
We are developing a best-in-class NAMPT inhibitor for the treatment of a range of solid tumor indications. Our approach leverages several novel insights and a synthetic lethality strategy to significantly increase the therapeutic index of our small molecules. Unlike other programs previously in the clinic against this target, we have developed a proprietary patient selection assay to identify the approximately 30% of patients with non-small cell lung, small cell lung, colorectal, ovarian, and other solid tumors with a signature that makes them much more likely to respond to our drug candidates. We have also engineered and optimized our molecules to mitigate the toxicities associated with other NAMPT inhibitors.
Our Investors
To support our work, in September 2021 we raised $40 million in a Series A financing led by Canaan Partners, with participation from Osage University Partners, Connecticut Innovations, HighCape Partners and Alexandria Venture Investments.
Join Our Team
We believe in cutting edge science and an inclusive environment